Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis

Q. Tang, D. Ramsköld, O. Krystufkova, HF. Mann, C. Wick, M. Dastmalchi, T. Lakshmikanth, Y. Chen, J. Mikes, H. Alexanderson, A. Achour, P. Brodin, J. Vencovsky, IE. Lundberg, V. Malmström,

. 2019 ; 89 (1) : e12732. [pub] 20181209

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012138
E-zdroje Online Plný text

NLK Free Medical Journals od 1997 do Před 1 rokem
Medline Complete (EBSCOhost) od 1972-01-01 do Před 1 rokem
Wiley Free Content od 1997 do Před 1 rokem

We aimed to evaluate in vivo effects of abatacept on phenotypes of T and B cells in the circulation of myositis patients in a sub-study of the ARTEMIS trial. Twelve patients with paired frozen PBMCs before and after 6-month abatacept treatment were included in this sub-study where mass cytometry (CyTOF) was chosen as a technology to be tested for its utility in a real-life clinical immune monitoring setting. Using CyTOF, the peripheral T cell phenotypes demonstrated considerable variation over time and between individuals precluding the identification of treatment-specific changes. We therefore conclude that studies of patient cohorts displaying wide clinical heterogeneity using mass cytometry must be relatively large in order to be suited for discovery research and immune monitoring. Still, we did find some correlations with functional muscle outcome, namely positive correlations between the ratio of CD4+ T cells and CD8+ T cells (CD4/CD8) in peripheral blood samples both at baseline and after treatment with muscle endurance improvement as assessed by the functional index-2 (FI-2) test. Our data suggest that the CD4/CD8 ratio in circulation at time of active disease may be a predictor of treatment efficacy in myositis patients.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012138
003      
CZ-PrNML
005      
20190416083934.0
007      
ta
008      
190405s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/sji.12732 $2 doi
035    __
$a (PubMed)30451307
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Tang, Quan $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
245    10
$a Effect of CTLA4-Ig (abatacept) treatment on T cells and B cells in peripheral blood of patients with polymyositis and dermatomyositis / $c Q. Tang, D. Ramsköld, O. Krystufkova, HF. Mann, C. Wick, M. Dastmalchi, T. Lakshmikanth, Y. Chen, J. Mikes, H. Alexanderson, A. Achour, P. Brodin, J. Vencovsky, IE. Lundberg, V. Malmström,
520    9_
$a We aimed to evaluate in vivo effects of abatacept on phenotypes of T and B cells in the circulation of myositis patients in a sub-study of the ARTEMIS trial. Twelve patients with paired frozen PBMCs before and after 6-month abatacept treatment were included in this sub-study where mass cytometry (CyTOF) was chosen as a technology to be tested for its utility in a real-life clinical immune monitoring setting. Using CyTOF, the peripheral T cell phenotypes demonstrated considerable variation over time and between individuals precluding the identification of treatment-specific changes. We therefore conclude that studies of patient cohorts displaying wide clinical heterogeneity using mass cytometry must be relatively large in order to be suited for discovery research and immune monitoring. Still, we did find some correlations with functional muscle outcome, namely positive correlations between the ratio of CD4+ T cells and CD8+ T cells (CD4/CD8) in peripheral blood samples both at baseline and after treatment with muscle endurance improvement as assessed by the functional index-2 (FI-2) test. Our data suggest that the CD4/CD8 ratio in circulation at time of active disease may be a predictor of treatment efficacy in myositis patients.
650    _2
$a abatacept $x terapeutické užití $7 D000069594
650    _2
$a dospělí $7 D000328
650    _2
$a podskupiny B-lymfocytů $x účinky léků $7 D016175
650    _2
$a dermatomyozitida $x krev $x farmakoterapie $x imunologie $7 D003882
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a imunosupresiva $x terapeutické užití $7 D007166
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a polymyozitida $x krev $x farmakoterapie $x imunologie $7 D017285
650    _2
$a T-lymfocyty - podskupiny $x účinky léků $7 D016176
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Ramsköld, Daniel $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Krystufkova, Olga $u Institute of Rheumatology Prague, Prague, Czech Republic.
700    1_
$a Mann, Herman F $u Institute of Rheumatology Prague, Prague, Czech Republic.
700    1_
$a Wick, Cecilia $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Dastmalchi, Maryam $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Lakshmikanth, Tadepally $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Chen, Yang $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Mikes, Jaromir $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Alexanderson, Helene $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden. Functional Area Occupational Therapy and Physical Therapy, Karolinska University Hospital, and Division of Physiotherapy, Department of NVS, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Achour, Adnane $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Brodin, Petter $u Science for Life Laboratory, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden. Department of Neonatology, Karolinska University Hospital, Stockholm, Sweden.
700    1_
$a Vencovsky, Jiri $u Institute of Rheumatology Prague, Prague, Czech Republic.
700    1_
$a Lundberg, Ingrid E $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
700    1_
$a Malmström, Vivianne $u Division of Rheumatology, Department of Medicine, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden.
773    0_
$w MED00010600 $t Scandinavian journal of immunology $x 1365-3083 $g Roč. 89, č. 1 (2019), s. e12732
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30451307 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190416083959 $b ABA008
999    __
$a ok $b bmc $g 1391448 $s 1050443
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 89 $c 1 $d e12732 $e 20181209 $i 1365-3083 $m Scandinavian journal of immunology $n Scand J Immunol $x MED00010600
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...